Synthesis and Antileukemic Activity of Novel 2‐(4‐(2,4‐dimethoxybenzoyl)phenoxy)‐1‐(4‐(3‐(piperidin‐4‐yl)propyl)piperidin‐1‐yl)ethanone Derivatives

Abstract

A series of novel 2-(4-(2,4-dimethoxybenzoyl)phenoxy)-1-(4-(3-(piperidin-4-yl)propyl) piperidin-1-yl)ethanone derivatives 9(a-e) and 10(a-g) were synthesized and characterized by 1 H NMR, IR, mass spectral, and elemental analysis. These novel compounds were evaluated for their antileukemic activity against two human leukemic cell lines (K562 and CEM) by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide assay. Some of the tested compounds showed good antiproliferative activity with IC 50 values ranging from 1.6 to 8.0 lM. Compound 9c, 9e, and 10f with an electron-withdrawing halogen substituent at the para position on the phenyl ring showed excellent in vitro potency against tested human leukemia cells (K562 and CEM).

Benzophenone: a ubiquitous scaffold in medicinal chemistry

“…61 In 2012, Rangappa et al synthesized novel molecules containing 2,4-dimethoxybenzophenone conjugated with piperidine analogues. 62 These molecules were tested for their antileukemic activities against two human leukemic cell lines (K562 and CEM) using MTT assays. All the synthesized compounds were found to have good IC 50 it involves benzoylation, Fries rearrangement, esterification, and an alkaline hydrolysis coupling reaction using TBTU/ lutidine, followed by an acid-mediated cyclization step.…”

Synthesis, anti-angiogenic and DNA cleavage studies of novel N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide derivatives

“…The use of combinatorial approaches toward the synthesis of drug-like scaffolds is a powerful tool in helping to speed up drug discovery. In the view of the facts mentioned above and as part of our initial efforts to discover potentially active new agents [ 35 – 37 ], we have synthesized some novel N -(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide derivatives as anticancer cancer agents, which have demonstrated efficient DNA binding and antiangiogenic activity.…”